<DOC>
	<DOCNO>NCT01507519</DOCNO>
	<brief_summary>1 . ) Indigenously develop design BioMimeTM - predictably safe &amp; efficacious 3rd generation drug elute stent ( DES ) - propensity minimize vascular injury use intelligent mix ultra-low strut thickness Co-Cr stent , - highly document drug Sirolimus &amp; - biocompatible , biodegradable polymer</brief_summary>
	<brief_title>Study Safety , Efficacy Biomime Stent Patients With Single , Discrete , De Novo , Non-Complex Coronary Lesions</brief_title>
	<detailed_description>- Principal Investigator : Dr. Sameer Dani , Interventional Cardiologist , Life Care Hospital , Ahmedbad . Mobile +91 98250 38855 . - Study Title : The First-In-Man Safety Performance Evaluation BiomimeTM Sirolimus-Eluting Stent System Treatment Patients Single , De novo , Non-complex Coronary Lesions - The BiomimeTM Pilot FiM Trial - Sponsor : Meril Life Sciences Pvt . Ltd. - Study device : BiomimeTM Sirolimus-Eluting Stent ( BiomimeTM SES , Meril Life Sciences ) - Study objective : To evaluate safety efficacy BiomimeTM SES . - Study design : Phase IV , prospective study conduct single centre ( Life Care Hospital , Ahmedbad ) - Study population : A total 30 patient stable unstable coronary disease , silent ischemia document evidence ischemia , angiography , , pre-specified subset , intravascular ultrasound ( IVUS ) 8-month follow-up . - Participating Centre : Life Care Hospital , Ahmedabad - QCA &amp; IVUS core lab : To decide . - Follow-up : All patient undergo clinical follow-up 1 , 6 , 12 24 month . All patient undergo angiographic follow-up 8 month . All patient submit intravascular ultrasound 8 month . - Primary safety endpoint : Major Adverse Cardiac Events ( MACE ) 30 day clinical follow-up . MACE define follow : cardiac death , myocardial infarction , ischemia driven target lesion revascularization ( TLR ) . - Primary efficacy endpoint : - In-stent luminal loss assess quantitative coronary angiography ( QCA ) 8-month follow-up - Percentage in-stent volume obstruction measure IVUS 8- month follow-up . - Secondary endpoint : - Occurrence Major Adverse Cardiac Events ( MACE ) define cardiac death , non-fatal acute myocardial infarction , need repeat target-lesion revascularization ( cardiac bypass graft repeat percutaneous coronary intervention 24 month follow-up . - Angiographic binary restenosis 8 month angiographic follow-up . - Other endpoint : - Rates stent thrombosis ( acute , sub-acute , late very-late ) 24 month follow-up - In-stent in-segment minimum lumen diameter ( MLD ) % diameter stenosis ( DS ) QCA 8-month angiographic follow-up . - In-stent acute gain post procedure QCA . - Late acquire incomplete stent apposition IVUS 8 month follow-up . - Primary analysis : The primary endpoint analyzed subject de novo coronary lesion enrol study ( intention treat )</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patient &gt; 18 year age ; Symptoms stable unstable angina and/or presence positive functional test ischemia ; Presence single de novo target lesion locate native coronary vessel suitable percutaneous treatment study stent ; Acceptable candidate coronary artery bypass graft ( CABG ) surgery ; The subject willing sign write informed consent prior procedure , willing undergo ALL study protocol followup , include angiographic ( IVUS ) followups 8 month . Target lesion locate major epicardial coronary vessel reference 2.53.5mm diameter ( visual estimation ) Target lesion ≤ 19mm length ( visual estimation ) treat ( cover ) one single study stent ( 19 24mm length ) ; ≥ 50 % &lt; 100 % diameter stenosis ; TIMI ( Thrombolysis In Myocardial Infarction ) flow grade ≥ 2 . Known hypersensitivity contraindication mTOR inhibitor class drug ( sirolimus ) , heparin , required medication include thienopyridines , cobalt chromium , contrast medium adequately pre medicate ; Patient female childbearing potential ; Pretreatment target lesion device balloon angioplasty ; Previous brachytherapy target vessel ; Presence nontarget vessel lesion require staged procedure ( ) &lt; 30 day index procedure ; Prior CABG surgery target vessel ; Previous percutaneous coronary intervention ( PCI ) CABG surgery &lt; 30 day index procedure date ; Acute myocardial infarction &lt; 3 day , cardiac enzyme elevation include total creatine kinase ( CK ) &gt; 2 time upper normal limit value and/or CKMB upper normal limit value within past 72 hour ; CK and/or CKMB level elevate upper normal limit value time index procedure ; Documented leave ventricular ejection fraction &lt; 30 % ; Renal insufficiency determine baseline serum creatinine &gt; 2.0/dl ; Thrombocytopenia baseline platelet count &lt; 100,000 cells/mm3 ; Anemia baseline hemoglobin &lt; 10g/dL ; Extensive peripheral vascular disease extreme anticoagulation precludes safe &gt; 5 French sheath insertion ; History bleed diathesis , coagulopathy , refuse blood transfusion ; Patients suffer stroke , transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) within past 6 month ; Significant gastrointestinal genitourinary bleed within past 6 month ; Patient recipient heart transplant ; Any elective surgical procedure plan within 12 month index procedure ; Known illness serious clinical condition life expectancy &lt; 2 year ; Participation active followup phase clinical trial within 6 month ; Impossibility comply antiplatelet therapy study clinical followup ; Any impossibility comply protocol followup . Target lesion vessel angiographic evidence moderate severe calcification ; Presence severe tortuosity ; Presence severe angulation ( &gt; 60o ) ; Presence intraluminal thrombus ; Target lesion involve bifurcation ( side branch ≥ 2.0mm ) ; Target lesion locate leave main stem ; Aortoostial lesion location ; Target lesion involve side branch reference diameter ≥ 2.0mm ; Presence significant stenosis ( &gt; 40 % ) target vessel either proximal distal target lesion untreated ; Previous placement stent within 10mm target lesion ; Total occlusion ( TIMI flow grade 0 1 ) ; Target lesion locate arterial vein graft ; Target lesion due instent restenosis ; Coronary anatomy unsuitable percutaneous treatment implantation available study stent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>